| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424189100 | Hepatitis virus | 72 |
| 20080220009 | Rodent hepatitis B virus core proteins as vaccine platforms and methods of thereof - The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations. | 09-11-2008 |
| 20090074805 | Yeast-based Therapeutic for Chronic Hepatitis C Infection - Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection. | 03-19-2009 |
| 20090087449 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 04-02-2009 |
| 20090098153 | Activation of HCV-specific T cells - The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4 | 04-16-2009 |
| 20090104217 | Pharmaceutical Composition Comprising An Antigen - The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected from neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer. | 04-23-2009 |
| 20090130135 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 05-21-2009 |
| 20090155294 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatitis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 06-18-2009 |
| 20090186045 | USE OF CONSENSUS SEQUENCE AS VACCINE ANTIGEN TO ENHANCE RECOGNITION OF VIRULENT VIRAL VARIANTS - The invention provides consensus sequences for hepatitis C virus 1a and 1b. Also provided are non-synonymous changes for each residue of the consensus sequences. These sequences are useful as compositions or vaccines for prophylactic use or treating HCV-infected individuals. Also provided are methods for lessening the chances for a HCV-infected individual to enter a chronic phase of infection and methods of diagnosing an individual with HCV 1a or HCV 1b infection. | 07-23-2009 |
| 20090186046 | Hepatitis C Virus Non Structural Fusion Protein - The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof for treating or preventing HCV infections, HCV-associated diseases and pathologic conditions as well as a method of inducing or stimulating an immune response against HCV in a host organism. | 07-23-2009 |
| 20090186047 | HCV Vaccinations - The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times. | 07-23-2009 |
| 20090252755 | CLONED GENOME OF INFECTIOUS HEPATITIS C VIRUS STRAIN HC-TN AND USES THEREOF - Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1 | 10-08-2009 |
| 20090258033 | HCV E1E2 vaccine compositions - HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject. | 10-15-2009 |
| 20090263413 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USE THEREOF IN PHARMACEUTICALS - A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G) | 10-22-2009 |
| 20100008941 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5 | 01-14-2010 |
| 20100034844 | Activation of HCV Specefic T Cells - Methods for activating HCV-specific T cells are described. The methods utilize one or more administrations of HCV protein compositions, followed by one or more administrations of a viral vector comprising a nucleic acid encoding a least one HCV epitope that is present in the first composition. The protein compositions can further comprise an immunostimulatory nucleic acid and or other adjuvants and immune stimulatory compounds. | 02-11-2010 |
| 20100034845 | AVIAN HEPATITIS E VIRUS, VACCINES AND METHODS OF PROTECTING AGAINST AVIAN HEPATITIS-SPLENOMEGALY SYNDROME AND MAMMALIAN HEPATITIS E - The present invention relates to a novel isolated avian hepatitis E virus having a nucleotide sequence set forth in SEQ ID NO:1 or its complementary strand. The invention further concerns immunogenic compositions comprising this new virus or recombinant products such as the nucleic acid and vaccines that protect an avian or mammalian species from viral infection or hepatitis-splenomegaly syndrome caused by the hepatitis E virus. Also included in the scope of the invention is a method for propagating, inactivating or attenuating a hepatitis E virus comprising inoculating an embryonated chicken egg with a live, pathogenic hepatitis E virus and recovering the virus or serially passing the pathogenic virus through additional embryonated chicken eggs until the virus is rendered inactivated or attenuated. Further, this invention concerns diagnostic reagents for detecting an avian hepatitis E viral infection or diagnosing hepatitis-splenomegaly syndrome in an avian or mammalian species comprising an antibody raised or produced against the immunogenic compositions and antigens such as ORF2 proteins expressed in a baculovirus vector, | 02-11-2010 |
| 20100068218 | Optimized Multi-Epitope Constructs and Uses Thereof - The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity. | 03-18-2010 |
| 20100074916 | AVIAN INFLUENZA VACCINE - H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines. | 03-25-2010 |
| 20100092503 | HCV FUSION POLYPEPTIDEDS - The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize against HCV. | 04-15-2010 |
| 20100183652 | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS - A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule. | 07-22-2010 |
| 20100203074 | COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR DISEASES - The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated. | 08-12-2010 |
| 20100215682 | DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION - Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1. | 08-26-2010 |
| 20100266624 | HEPATITIS-C VIRUS TESTING - New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping. | 10-21-2010 |
| 20100291130 | CLONED GENOME OF INFECTIOUS HEPATITIS C VIRUS STRAIN HC-TN AND USES THEREOF - Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated. | 11-18-2010 |
| 20110002955 | ANTI-OBESE IMMUNOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESE VACCINE COMPOSITION COMPRISING THE SAME - Disclosed is an immunogenic hybrid polypeptide for the prevention and treatment of obesity, in which a mimetic peptide of a B cell epitope of apolipoprotein B-IOO; a rabies virus helper T cell epitope or hepatitis B virus surface antigen helper T cell epitope and a C-terminal peptide fragment of mouse apolipoprotein Cu or a mimetic peptide of a B cell epitope of apolipoprotein B-100 are fused to each other in that order in the direction from the N terminus to the C terminus thereof. Also, a vaccine composition for the prevention and treatment of obesity, comprising the immunogenic hybrid polypeptide is disclosed, along with a polynucleotide encoding the immunogenic hybrid polypeptide, a recombinant expression vector carrying the polynucleotide, a host cell anchoring the recombinant expression vector, and a method for producing the immunogenic hybrid polypeptide by culturing the host cell transformed with the recombinant expression vector. | 01-06-2011 |
| 20110070255 | IMMUNOGENIC PEPTIDE COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (Aβ) peptide linked to a helper T cell epitope (Th) having multiple class II MHC binding motifs. The peptide immunogen elicits a site-directed immune response against the main functional/regulatory site of the Aβ peptide and generate antibodies, which are highly cross-reactive to the soluble Aβ | 03-24-2011 |
| 20110091495 | HCV E2 CONSTRUCT COMPOSITIONS AND METHODS - A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal sequence, the ectodomain of HCV E2 sequence truncated at aa 664, a thrombin cleavage site and a human Fc domain. The method also relates to an expression system for the construct, which is stably expressed in human embryonic kidney cells 293T. Continuous protein expression in a bioreactor allows for 4 mg of purified protein per liter of cell supernatant. | 04-21-2011 |
| 20110129489 | METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR - The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern. | 06-02-2011 |
| 20110177110 | COMPOSITIONS COMPRISING CATIONIC MICROPARTICLES AND HCV E1E2 DNA AND METHODS OF USE THEREOF - Immunogenic HCV E1E2 | 07-21-2011 |
| 20110206711 | METHOD FOR INDUCING CYTOTOXIC T-CELLS, CYTOTOXIC T-CELL INDUCER, AND PHARMACEUTICAL COMPOSITION AND VACCINE EMPLOYING SAME - A method for inducing cytotoxic T-cells that includes binding to an HLA molecule on the surface of a cell that is a target of a cytotoxic T-cell a peptide containing one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 13 and consisting of not less than 8 and not more than 11 amino acid residues, or a peptide derived from a precursor thereof. | 08-25-2011 |
| 20110300169 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIGEN - The invention relates to immunogenic compositions. In certain embodiments, the invention provides pharmaceutical compositions comprising an antigen, an immunostimulating substance selected form neuroactive compounds, hormones, compounds having a growth hormone activity, and mixtures thereof, and a polycationic polymer. | 12-08-2011 |
| 20110300170 | HCV VACCINES - Disclosed are methods and compositions for inducing immune responses against Hepatatis C virus (HCV). The compositions comprise one or more epitope from a hotspot epitope. In certain embodiments, an HCV vaccine comprising at least two epitopes, each from a different hotspot epitope, is provided. | 12-08-2011 |
| 20120034256 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 02-09-2012 |
| 20120070456 | POLYPEPTIDE CARRIER PROTEIN - The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years. | 03-22-2012 |
| 20120093849 | Agents for Treatment of HCV and Methods of Use - An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes permits identification of compounds and protocols which are useful in the treatment of HCV infection. Also useful in the invention are mimics, or function-disrupting ligands, of an amphipathic helix of the nonstructural proteins described herein and antibodies and fragments thereof immunoreactive with said helix. | 04-19-2012 |
| 20120100170 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS C - The present invention provides compositions and methods for delivery of one or more hepatitis C virus (HCV) antigens using a bacterium recombinantly encoding and expressing such antigens. In certain embodiments, the bacterial platform comprises the use of attenuated and killed but metabolically active forms of | 04-26-2012 |
| 20120189648 | INFECTIOUS HEPATITIS C VIRUSES OF GENOTYPE 3A AND 4A AND USES THEREOF - The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis C virus. In particular, invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis C viruses of either genotype 3a (strain S52) or genotype 4a (strain ED43). The invention therefore relates to the use of the nucleic acid sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and in the development of screening assays for the identification of antiviral agents for HCV. The invention therefore also relates to the use of viral particles derived from laboratory animals infected with S52 and ED43 viruses. | 07-26-2012 |
| 20120301494 | PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR - This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. | 11-29-2012 |
| 20120308594 | HCV CLADE AND PROTOTYPE SEQUENCES THEREOF - The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses. | 12-06-2012 |
| 20130071421 | TURKEY VIRAL HEPATITIS VIRUS AND USES THEREOF - Isolated a Turkey Viral Hepatitis picomavirus-like viruses associated with Turkey viral hepatitis, and isolated nucleic acid sequences and polypeptides are disclosed. Antibodies against antigens from Turkey Viral Hepatitis picornavirus-like viruses, iRNAs which target nucleic acid sequences of the Turkey Viral Hepatitis picornavirus-like virus, methods for detecting the presence or absence of Turkey Viral Hepatitis picomavirus-like viruses in an animal, and immunogenic compositions for inducing an immune response against Turkey Viral Hepatitis picomavirus-like viruses in an animal are also disclosed. | 03-21-2013 |
| 20130071422 | ADJUVANTED VACCINES FOR SEROGROUP B MENINGOCOCCUS - An immunogenic composition comprises (i) an immuno stimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex, and (ii) a meningococcal serogroup B antigen. In most embodiments, the composition does not include an aluminium salt and does not include an oil-in-water emulsion. | 03-21-2013 |
| 20130171182 | INFLUENZA VACCINE - The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface polypeptide M2 or a fragment thereof in the e | 07-04-2013 |
| 20130243805 | Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 09-19-2013 |
| 20130337001 | Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C - This disclosure provides an immunogenic composition comprising an amount of isolated dendritic cells comprising at least one fragment of a hepatitis C protein selected from the group consisting of the core protein of hepatitis C and the NS3 protein of hepatitis C, the fragment does not suppress activity of dendritic cells and is effective to produce an immunogenic response against hepatitis C infection and optionally T-lymphocytes activated for a Th1 response. This disclosure also provides a method and a kit for preparing the above composition. Further, this disclosure provides a method for treating or reducing the severity of hepatitis C and a method for enhancing immunoresponse in a patient suffering from hepatitis C virus infection by administering to the patient in need of the treatment the above composition. Finally, this disclose provides a use of the above composition for treating hepatitis C virus infection. | 12-19-2013 |
| 20130337002 | PEPTIDE SCAFFOLD DESIGN - The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis. | 12-19-2013 |
| 20140065182 | YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 03-06-2014 |
| 20140099335 | DNA VACCINE - The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. | 04-10-2014 |
| 20140120127 | RECOMBINANT HCV E2 GLYCOPROTEIN - The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof. | 05-01-2014 |
| 20140193450 | PEPTIDE CARRIER FUSION PROTEINS AS ALLERGY VACCINES - The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide. | 07-10-2014 |
| 20140199338 | VACCINES FOR PROTECTION FROM AND TREATMENT OF ALZHEIMER'S DISEASE - Disclosed herein are DNA-based vaccines against amyloid β peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid β peptides, such as amino acids 1-11 of Aβ, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant. | 07-17-2014 |
| 20140220063 | VACCINE COMPOSITION - The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter. | 08-07-2014 |
| 20140286984 | Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 09-25-2014 |
| 20140286985 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 09-25-2014 |
| 20140302082 | NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLES - A subgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon RNA (nucleic acid) having an excellent autonomously replicating ability and infectious HCV particle-producing ability, each derived from a novel HCV of genotype 1b, are provided. Particularly, a subgenomic replicon RNA (nucleic acid) and a fullgenomic replicon RNA (nucleic acid), each derived from an HCV genome of the NC1 strain which is a novel HCV genotype 1b isolated from a patient with acute severe hepatitis C, are provided. | 10-09-2014 |
| 20140348866 | GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections. | 11-27-2014 |
| 20150017197 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 01-15-2015 |
| 20150071955 | GB VIRUS C (HEPATITIS G VIRUS) E2 GLYCOPROTEIN AS AN IMMUNOMODULATORY AGENT - GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. | 03-12-2015 |
| 20150086580 | RATIONAL VACCINE DESIGN FOR HEPATITIS C VIRUS - Compositions and methods are provided relating to HCV E2 protein and modifications thereto which enhance the immunogenicity of the protein for vaccine development with respect to the generation of a neutralizing immune response. | 03-26-2015 |
| 20150110828 | YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 04-23-2015 |
| 20150307558 | CHIMERIC VACCINE ANTIGENS AGAINST HEPATITIS C VIRUS - The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components. | 10-29-2015 |
| 20150335735 | PEPTIDE CARRIER FUSION PROTEINS AS ALLERGY VACCINES - The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide. | 11-26-2015 |
| 20150344529 | VACCINE FOR HPV INFECTION AND/OR HEPATITIS B COMPRISING HPV/HBS CHIMERIC PROTEIN AS ACTIVE INGREDIENT - A chimeric protein of HPV-L2 peptide and HBs protein wherein the HPV-L2 peptide is (1) a peptide consisting of the core sequence region of 20 amino acid residues, (2) a peptide inside the core sequence region comprising 6 amino acid residues Gly-Gly-Leu-Gly-Ile-Gly or (3) a peptide consisting of 70 or less amino acid residues obtained by adding an amino acid sequence derived from HPV L2 protein at the N-terminal and/or the C-terminal of the core sequence region; and a vaccine for HPV infection and/or hepatitis B comprising the chimeric protein as an active ingredient. A vaccine comprising the chimeric protein of the present invention is the one that has an increased expression level in a host, an enhanced immune ability (early antibody induction) and a broader spectrum effective for a number of HPV types. | 12-03-2015 |
| 20160008459 | IMMUNOGENIC POLYPEPTIDE SURFACE LAYER-EXPRESSING BIFIDOBACTERIUM | 01-14-2016 |
| 20160015804 | VACCINE COMBINATIONS - Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided. | 01-21-2016 |
| 20160039883 | PALIVIZUMAB EPITOPE-BASED VIRUS-LIKE PARTICLES - The present disclosure generally relates to immunogens for eliciting an antibody response against respiratory syncytial virus (RSV). More specifically, the present disclosure relates to virus-like particles (VLPs) including a RSV F protein epitope, as well as methods of use thereof. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and young children (Hall et al., NEJM, 360:5888-598, 2009; and Nair et al., Lancet, 375:1545-1555, 2010) and a vaccine to protect this young population is of high priority. | 02-11-2016 |
| 20160051665 | INDUCTION OF IMMUNE RESPONSE - Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue. | 02-25-2016 |
| 20160067332 | E1E2 HCV VACCINES AND METHODS OF USE - The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual. | 03-10-2016 |
| 20160068581 | PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE - The present disclosure is directed to individual Aβ peptide immunogen constructs, peptide compositions comprising these Aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these Aβ peptide immunogen constructs, with the individual Aβ peptide immunogen constructs having the N-terminus of the Aβ peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the Aβ peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease. | 03-10-2016 |
| 20160136264 | HEPATITIS B VACCINE - Disclosed is a composition comprising: i) HBsAg, a fragment thereof, a variant thereof, or the mixture of at least two of them, ii) HBcAg1-X, a fragment thereof, a variant of the antigen or the antigen fragment, or the mixture of at least two of them, wherein X is an integer of from 149 to 183, iii) CpG-ODN, 21 bases long, which is a phosphorothioate oligonucleotide and includes two or more copies of 5′-NTCGTT-3′ motifs. The use of the composition in the treatment of HBV-infection and HBV-induced diseases, and the therapy methods of HBV-infection and HBV-induced diseases are also disclosed. | 05-19-2016 |
| 20160144011 | COMPOSITION AND USES THEREOF - The present invention provides a particle comprising a fusion protein, wherein the fusion protein comprises at least one NANP repeat (SEQ ID NO: 7), some or all of the C-terminus of the CS protein from | 05-26-2016 |
| 20160185826 | VIRUS-LIKE PARTICLE VACCINES - The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions. | 06-30-2016 |
| 20190144840 | HBV Polymerase Mutants | 05-16-2019 |
